Interferon-β therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis

Immunology

Volumn 121, Issue 1, 2007, Pages 29-39

  Zafranskaya, Marina ^a,b   Oschmann, Patrick ^b   Engel, Rosel ^a,b   Weishaupt, Andreas ^c   Van Noort, Johannes M ^d   Jomaa, Hassan ^a,b   Eberl, Matthias ^a,e  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d TNO   (Netherlands)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

Autoimmunity; CFSE (5 (and 6 ) carboxyfluorescein diacetate succinimidyl ester); Disease progression; Immunotherapy; Myelin antigens; T cell responses

Indexed keywords

BETA1A INTERFERON; CD45RO ANTIGEN; CYTOKINE; INTERFERON BETA SERINE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; EX VIVO STUDY; FEMALE; FUNCTIONAL STATUS; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VITRO STUDY; MALE; MEMORY CELL; MULTIPLE SCLEROSIS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL;

ADULT; ANTIGENS, CD45; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DISEASE PROGRESSION; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; LYMPHOCYTE ACTIVATION; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELIN-ASSOCIATED GLYCOPROTEIN; T-LYMPHOCYTE SUBSETS;

EID: 34047240587     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2006.02518.x     Document Type: Article

References (70)

1. Hafler DA, Slavik JM, Anderson DE, O'Connor KC, de Jager P, Baecher-Allan C. Multiple sclerosis. Immunol Rev 2005; 204:208-31.
2. Hafler DA. Degeneracy, as opposed to specificity, in immunotherapy. J Clin Invest 2002; 5:581-4.
3. Kieseier BC, Hemmer B, Hartung HP. Multiple sclerosis - novel insights and new therapeutic strategies. Curr Opin Neurol 2005; 18:211-20.
4. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23:683-747.
5. IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:655-61.
6. Paty DW, Li DK, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:662-7.
7. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (α/β) in immunity and autoimmunity. Annu Rev Immunol 2005; 23:307-36.
8. Rudick RA, Carpenter CS, Cookfair DL, Tuohy VK, Ransohoff RM. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurology 1993; 43:2080-7.
9. Noronha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993; 46:145-53.
10. Pette M, Pette DF, Muraro PA, Farnon E, Martin R, McFarland HF. Interferon-β interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes. Neurology 1997; 49:385-92.
11. Lindert RB, Haase CG, Brehm U, Linington C, Wekerle H, Hohlfeld R. Multiple sclerosis. B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain 1999; 122:2089-99.
12. van Noort JM, Bajramovic JJ, Plomp AC, van Stipdonk MJ. Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis. J Neuroimmunol 2000; 105:46-57.
13. Danke NA, Koelle DM, Yee C, Beheray S, Kwok WW. Autoreactive T cells in healthy individuals. J Immunol 2004; 172: 5967-72.
14. Hellings N, Barée M, Verhoeven C, D'hooghe MB, Medaer R, Bernard CC, Raus J, Stinissen P. T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls. J Neurosci Res 2001; 63:290-302.
15. Iglesias A, Bauer J, Litzenburger T, Schubart A, Linington C. T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia 2001; 36:220-34.
16. + T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 2002; 125:538-50.
17. Pelfrey CM, Rudick RA, Cotleur AC, Lee JC, Tary-Lehmann M, Lehmann PV. Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J Immunol 2000; 165:1641-51.
18. van der Aa A, Hellings N, Bernard CA, Raus J, Stinissen P. Functional properties of myelin oligodendrocyte glycoproteinreactive T cells in multiple sclerosis patients and controls. J Neuroimmunol 2003; 137:164-76.
19. Arbour N, Holz A, Sipe JC, Naniche D, Romine JS, Tyroff J, Oldstone MB. A new approach for evaluating antigen-specific T cell responses to myelin antigens during the course of multiple sclerosis. J Neuroimmunol 2003; 137:197-209.
20. Mannering SI, Morris JS, Stone NI, Jensen PK, Purcell AW, Honeyman MC, van Endert PM, Harrison LC. A sensitive method for detecting proliferation of rare autoantigen-specific human T cells. J Immunol Meth 2003; 283:173-83.
21. + T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 2004; 103:4222-31.
22. + T-cell responses after dendritic cell-based immunotherapy using CFSE due dilution analysis. J Clin Immunol 2004; 24:653-63.
23. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13:227-31.
24. Smith PA, Heijmans N, Ouwerling B, et al. Native myelin oligodendrocyte glycoprotein promotes severe chronic neurological disease and demyelination in Biozzi ABH mice. Eur J Immunol 2005; 35:1311-19.
25. Meinl E, Weber F, Drexler K, et al. Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. J Clin Invest 1993; 92:2633-43.
26. Eberl M, Engel R, Beck E, Jomaa H. Differentiation of human cd T cells towards distinct memory phenotypes. Cell Immunol 2002; 218:1-6.
27. Fulcher DA, Wong SW. Carboxyfluorescein succinimidyl esterbased proliferative assay for assessment of T cell function in the diagnostic laboratory. Immunol Cell Biol 1999; 77:559-64.
28. Koehler NK, Genain CP, Giesser B, Hauser SL. The human T cell response to myelin oligodendrocyte glycoprotein: a multiple sclerosis family-based study. J Immunol 2002; 168:5920-7.
29. Friese MA, Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain 2005; 128:1747-63.
30. Hemmer B, Archelos JJ, Hartung H. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002; 3:291-301.
31. + T cells in multiple sclerosis and its animal models. Curr Drug Targets Inflamm Allergy 2005; 4:239-45.
32. + T cell responses to human myelin protein-derived peptides. Proc Natl Acad Sci USA 1994; 91:10859-63.
33. + T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; 192:393-404.
34. + cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J Immunol 2004; 172:5120-7.
35. Seamons A, Perchellet A, Goverman J. Immune tolerance to myelin proteins. Immunol Res 2003; 28:202-21.
36. Hartung HP, Bar-Or A, Zoukos Y. What do we know about the mechanism of action of disease-modifying treatment in MS? J Neurol 2004; 251 (Suppl. 5):v12-v29.
37. Kerlero de Rosbo N, Milo R, Lees MB, Burger D, Bernard CC, Ben-Nun A. Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest 1993; 92:2602-8.
38. + T cells in patients with multiple sclerosis. J Neurol Sci 2005; 235:11-17.
39. Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, Racke MK. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. J Clin Invest 1998; 101:725-30.
40. Schumacher TN, Heemels MT, Neefjes JJ, Kast WM, Melief CJ, Ploegh HL. Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell 1990; 62:563-7.
41. Blachère NE, Morris HK, Braun D, Saklani H, di Santo JP, Darnell RB, Albert ML. IL-2 is required for the activation of memory CD8+ T cells via antigen cross-presentation. J Immunol 2006; 176:7288-300.
42. Calzascia T, di Berardino-Besson W, Wilmotte R, Masson F, de Tribolet N, Dietrich PY, Walker PR. Cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain. J Immunol 2003; 171:2187-91.
43. Ackerman AL, Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 2004; 5:678-84.
44. Heath WR, Belz GT, Behrens GM, et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004; 199:9-26.
45. + T helper-antigen-presenting cells. J Immunol 2005; 174:7497-505.
46. Neijssen J, Herberts C, Drijfhout JW, Reits E, Janssen L, Neefjes J. Cross-presentation by intercellular peptide transfer through gap junctions. Nature 2005; 434:83-8.
47. Hon H, Oran A, Brocker T, Jacob J. B lymphocytes participate in cross-presentation of antigen following gene gun vaccination. J Immunol 2005; 174:5233-42.
48. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human γδ T cells. Science 2005; 309:264-8.
49. Nguyen LT, Ramanathan M, Munschauer F, et al. Flow cytometric analysis of in vitro proinflammatory cytokines secretion in peripheral blood from multiple sclerosis patients. J Clin Immunol 1999; 19:179-85.
50. Nguyen LT, Ramanathan M, Weinstock-Guttman B, Baier M, Brownscheidle C, Jacobs LD. Sex differences in in vitro proinflammatory cytokine production from peripheral blood of multiple sclerosis patients. J Neurol Sci 2003; 15:93-9.
51. Hemmer B, Vergelli M, Calabresi P, Huang T, McFarland HF, Martin R. Cytokine phenotype of human autoreactive T clones specific for the immunodominant myelin basic protein peptide (83-99). J Neurosci Res 1996; 45:852-62.
52. + T cells in multiple sclerosis. J Immunol 2004; 172:3893-904.
53. + T-cells and disability score in relapsing-remitting multiple sclerosis. Cytokine 2005; 32:111-16.
54. Fernández O, Arbizu T, Izquierdo G, Martínez-Yélamos A, Gata JM, Luque G. Clinical benefits of interferon beta-1a in relapsingremitting MS. a phase IV study. Acta Neurol Scand 2003; 107:7-11.
55. Rieckmann P, Toyka KV, Multiple Sclerosis Therapy Consensus Group. Escalating immunotherapy of multiple sclerosis - new aspects and practical application. J Neurol 2004; 251:1329-39.
56. Kilinc M, Saatci-Cekirge I, Karabudak R. Serial analyses of soluble intracellular adhesion molecule-1 level in relapsing-remitting multiple sclerosis patients during IFN-β1b treatment. J Interferon Cytokine Res 2003; 23:127-33.
57. Espejo C, Brieva L, Ruggiero G, Río J, Montalban X, Martínez-Cáceres EM. IFN-β treatment modulates the CD28/CTLA-4 mediated pathway for IL-2 production in patients with relapsing remitting multiple sclerosis. Mult Scler 2004; 10:630-5.
58. Pellegrini P, Totaro R, Contasta I, Berhella AM, Russo T, Carolei A, Adorno D. IFN-β1a treatment and reestablishment of Th1 regulation in MS patients: dose effects. Clin Neuropharmacol 2004; 27:258-69.
59. Mitsdoerffer M, Schreiner B, Kieseier BC, Neuhaus O, Dichgans J, Hartung HP, Weller M, Wiendl H. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is unregulated by interferon-β in vitro and in vivo: rationale for the therapy of multiple sclerosis. J Neuroimmunol 2005; 159:155-64.
60. Totaro R, Passacantando A, Russo T, Parzanese I, Racsente M, Marini C, Tonietti G, Carolei A. Effect of interferon beta, cyclophosphamide and azathioprine on cytokine profile in patients with multiple sclerosis. Int J Immunopathol Pharmacol 2005; 18:377-83.
61. Gelati M, Corsini E, Dufour A, Massa G, La Mantia L, Milanese C, Nespolo A, Salmaggi A. Immunological effects of in vivo interferon-β1b treatment in ten patients with multiple sclerosis: a 1-year follow-up. J Neurol 1999; 1246:569-73.
62. Kraus J, Ling AK, Hamm S, Voigt K, Oschmann P, Engelhardt B. Interferon-β stabilizes barrier characteristics of brain endothelial cells in vitro. Ann Neurol 2004; 56:192-205.
63. Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, Weller M, Wiendl H. Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol 2004; 155:172-82.
64. Oh U, Yamano Y, Mora CA, et al. Interferon-β1a therapy in human T-lymphotropic virus type I-associated neurologic disease. Ann Neurol 2005; 57:526-34.
65. Gniadek P, Aktas O, Wandinger KP, et al. Systemic IFN-β treatment induces apoptosis of peripheral immune cells in MS patients. J Neuroimmunol 2003; 137:187-96.
66. + regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199:971-9.
67. Pede PD, Visintini D, Telera A, Cucurachi L, Campanini C, Immovilli P, Vescovini R, Sansoni P. Immunomodulatory effects of IFN-β1a treatment alone or associated with pentoxifylline in patients with relapsing-remitting multiple sclerosis (RRMS). J Interferon Cytokine Res 2005; 25:485-9.
68. Petereit HF, Bamborschke S, Esse AD, Heiss WD. Interferon gamma producing blood lymphocytes are decreased by interferon beta therapy in patients with multiple sclerosis. Mult Scler 1997; 3:180-3.
69. Furlan R, Bergami A, Lang R, et al. Interferon-β treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-γ and interleukin-4. J Neuroimmunol 2000; 111:86-92.
70. Franciotta D, Zardini E, Bergamaschi R, Andreoni L, Cosi V. Interferon γ and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment. J Neurol Neurosurg Psychiatry 2003; 74: 123-6.